Oculis Elects Biotech CFO Veteran Gregory Perry to Board Amid Financial Losses
Event summary
- Oculis reported a CHF 33.67M loss for 2025, with accumulated losses reaching CHF 80.25M.
- Gregory D. Perry, former CFO of Merus N.V., elected to Oculis' Board of Directors.
- Shareholders approved a capital band allowing issuance of up to 31.02M shares.
- Board authorized issuance of 5.75M treasury shares for potential ATM offerings.
- Executive compensation packages approved, including USD 2.5M fixed and USD 1.8M variable for 2027.
The big picture
Oculis' election of Gregory Perry signals a strategic focus on navigating U.S. capital markets, crucial for a biotech company with three late-stage ophthalmology candidates. The financial losses underscore the challenges of developing innovative treatments in a competitive sector. The expanded capital band provides flexibility for future fundraising, but investors will scrutinize how the company balances growth with financial sustainability.
What we're watching
- Financial Stability
- Whether Oculis can sustain its aggressive R&D pipeline amid mounting losses.
- Board Influence
- How Gregory Perry's biotech CFO experience will shape Oculis' U.S. capital markets strategy.
- Capital Strategy
- The pace at which Oculis will utilize its newly expanded capital band for fundraising.
Related topics